Fennec Pharmaceuticals vs Pelthos Therapeutics
FENC and PTHS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FENC and PTHS compare
Fennec Pharmaceuticals is the larger company, worth 14 times as much as Pelthos Therapeutics ($407M against $28.5M).
Fennec Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 3.1% compared with −152% at Pelthos Therapeutics.
Fennec Pharmaceuticals scores higher on the StockData Score (8 against 2 for Pelthos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FENC | PTHS |
|---|---|---|
| Size and price | ||
| Market cap | $407M | $28.5M |
| Share price | $11.62 | $7.44 |
| Change, 1 year | 49.4% | −80.1% |
| Change, 5 years | 18.3% | – |
| Beta (5Y) | 0.82 | – |
| Employees | 35 | 92 |
| StockData Score | ||
| Total score | 8 (better) | 2 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 387× | – |
| P/S | 6.1× | 0.6× (better) |
| P/B | 8.3× | – |
| EV/EBITDA | 96.5× | – |
| FCF yield | – | −114% |
| Fair value | $3.92 | – |
| Margin of safety | −196% | – |
| Growth | ||
| Revenue growth (TTM) | 71.1% | – |
| Revenue growth, 5Y average | 195% | – |
| Profitability | ||
| Gross margin | – | 83.2% |
| Operating margin | 5.6% (better) | −102% |
| Net margin | 3.1% (better) | −152% |
| FCF margin | – | −63.5% |
| Return on equity | 9.1% (better) | −300% |
| Return on invested capital | – | −408% |
| Financial health | ||
| Interest coverage | 11.7× (better) | −6.3× |
| Current ratio | 6.11 (better) | 1.78 |
| Altman Z-score | 5.30 (better) | −1.90 |
| Piotroski F-score | 1 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 46.5% | 35.6% |
| Insider net buying, 12 months | −$9.6M | $794K (better) |
Go deeper
- FENC stock overview
- FENC income statement
- FENC valuation and score
- PTHS stock overview
- PTHS income statement
- PTHS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.